KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Debt to Equity (2018 - 2026)

Takeda Pharmaceutical has reported Debt to Equity over the past 9 years, most recently at $0.56 for Q1 2026.

  • For Q1 2026, Debt to Equity fell 50.86% year-over-year to $0.56; the TTM value through Mar 2026 reached $0.56, down 50.86%, while the annual FY2026 figure was $0.56, 50.86% down from the prior year.
  • Debt to Equity was $0.56 for Q1 2026 at Takeda Pharmaceutical, down from $1.14 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.14 in Q1 2025 and bottomed at $0.11 in Q1 2024.
  • The 5-year median for Debt to Equity is $0.56 (2026), against an average of $0.53.
  • Year-over-year, Debt to Equity crashed 83.43% in 2024 and then soared 900.81% in 2025.
  • Over 5 years, Debt to Equity stood at $0.12 in 2022, then soared by 489.61% to $0.69 in 2023, then crashed by 83.43% to $0.11 in 2024, then soared by 900.81% to $1.14 in 2025, then plummeted by 50.86% to $0.56 in 2026.
  • The last three reported values for Debt to Equity were $0.56 (Q1 2026), $1.14 (Q1 2025), and $0.11 (Q1 2024) per Business Quant data.